Inhibitors of the enzyme purine nucleoside phosphorylase

Bibliography

• WEINBLATT ME, COBLYN JS, FRASER PA et al.: Cyclo-sporin A treatment of refractory rheumatoid arthritis. Arthr. Rheum. (1987) 30:11–17.
   PubMed Web of Science ®Google Scholar
• DOUGADOS M, AMOR B: Cyclosporin A in rheumatoid arthritis: preliminary clinical results of an open trial. Arthr. Rheum. (1987) 30:83-87. Clinical activity of Cyclosporin A against rheumatoid arthritis and its effects on T-cells.
   Google Scholar
• NICKOLOFF BJ, GRIFFITHS CEM: Lymphocyte traffick-ing in psoriasis: a new perspective emphasizing the dermal dendrocyte with active dermal recruitment mediated via endothelial cells followed by intra-epidermal T-cell activation. J. Invest. Dermatol (1990) 95 (Supp0 :35S–7S.
   Google Scholar
• ELLIS CN, GORSULOWSKY DC, HAMILTON TA: Cyclo-sporin improves psoriasis in a double-blind study. JAMA (1986) 256:3110-3116. Clinical activity of cyclosporin A against psoriasis and its ef-fects on T-cells.
   Google Scholar
• BOREL JF, FEURER C, MAGWEE C, STAHEILIN H: Effects of the new anti-lymphocytic peptide cyclosporin A in animals. Immunology (1977) 32:1017–1025.
   PubMed Web of Science ®Google Scholar
• BOREL JF, FEURER C, GUBLER HU, STAHELIN H: Biologi-cal effects of cyclosporin A: a new antilymphocytic agent. Agents Actions (1976) 6:468–475.
   PubMedGoogle Scholar
• GOTTIEB SL, HEFLER NS, GILLEAUDEAU P et al.: Short term anthralin treatment augments therapeutic effi-cacy of cyclosporin in psoriasis: a clinical and patho-logic study. J. Am. Acad. Dermatol. (1995) 33:637–645.
   PubMedGoogle Scholar
• OTTERNESS IG, BLIVEN ML: The T cell as a therapeutic target. In: New Developments in Antirheumatic Therapy. Rainsford KD, Velo GP (Eds.), Kluwer Academic, Norwell, MA, (1989) 277–304.
   Google Scholar
• •Articles 5–8 describe the use of cyclosporin A for treating T-cell mediated disorders.
   Google Scholar
• FEUTREN G, MIHATSCH MJ, INTERNATIONAL KIDNEY BI-OPSY REGISTRY OF CYCLOSPORINE IN AUTOIMMUNE DISEASES: Risk factors for cyclosporine-induced neph-rotoxicity in patients with autoimmune diseases. New Engl. J. Med. (1992) 326:1654. Toxicity of cyclosporin A.
   Google Scholar
• ST. GEORGIEV V: Enzymes of the purine metabolism: inhibition and therapeutic potential. Ann. NY Acad. Sci. (1993) 685:207–215.
   PubMed Web of Science ®Google Scholar
• MONTGOMERY JA: Purine nucleoside phosphorylase: a target for drug design. Med. Res. Rev. (1993) 13:209–228.
   PubMed Web of Science ®Google Scholar
• •Review article.
   Google Scholar
• PARKS RE, Jr., STOECKLER JD, CAMBOR D, SAVARESE TM,CRABTREE GW, CHU S-H: Purine nucleoside phospho-rylase and 5'-methylthioadenosine phosphorylase: targets for chemotherapy. In: Molecular Actions and Tar-gets for Cancer Chemotherapeutic Agents. Sartoerlli A, Lazo, JS, Bertino JR (Eds.), Academic Press, New York (1981) 229–252.
   Google Scholar
• STOECKLER JD: Purine nucleoside phosphorylase: atarget for chemotherapy. In: Developments in Cancer Chemotherapy Glazer RI (Ed.), CRC Press, Boca Raton, (1984) 35–60. PNP review articles.
   Google Scholar
• ERION MD, TAKABAYASHI K, SMITH et al.: Purine nu-cleoside phosphorylase. 1. Structure-function studies. Biochemistry (1997) 36:11725–11734.
   Google Scholar
• ERION MD, STOECKLER JD, GUIDA WC, WALTER RL, EALICK SE: Purine nucleoside phosphorylase. 2. Cata-lytic mechanism. Biochemistry (1997) 36:11735–11748.
   Google Scholar
• STOECKLER JD, POIROT AF, SMITH RM et al.: Purine nu-cleoside phosphorylase. 3. Reversal of purine based specificity site-directed mutagenesis. Biochemistry (1997) 36:11749-11756. Recent mechanistic studies on PNP.
   Google Scholar
• MARKERT ML: Purine nucleoside phosphorylase defi-ciency. Immunodeficiency Rev. (1991) 3:45–81.
   PubMedGoogle Scholar
• •Review articles.
   Google Scholar
• Inhibitors of Ribonucleotide Diphosphate Red uctase Activity Cory JG, Cory AH (Eds.), Pergamon Press, New York (1989).
   Google Scholar
• •Review articles.
   Google Scholar
• EALICK SE, RULE SA, CARTER DC et al.: Three- dimensional structure of human erythrocytic purine nucleoside phosphorylase at 3.2 A resolution. J. Biol. Chem. (1990) 265:1812–1820.
   Google Scholar
• •References [19,20] describe the three-dimensional structure for PNP.
   Google Scholar
• NARAYANA SV, BUGG CE, EALICK SE: Refined structure of purine nucleoside phosphorylase at 2.75 A resolu-tion. Acta ClysI (1997) D53:131–142.
   Google Scholar
• •References [19,20] describe the 3D structure for PNP.
   Google Scholar
• WILLIAMS SR, GODDARD JM, MARTIN DW, Jr.: Human purine nucleoside phosphorylase cDNA sequence and genomic clone characterization. Nucleic Acids Res. (1984) 12:5779-5787. Amino acid sequence for human erythrocytic PNP.
   Google Scholar
• EALICK, SE, BABU, YS, BUGG CE et al.: Application of crystallographic and modelling methods in the design of purine nucleoside phosphorylase inhibitors. Proc. Natl Acad. Sci. USA (1991) 88:11540–11544.
   PubMed Web of Science ®Google Scholar
• ••Detailed account of the structure-based design of PNPinhibitors.
   Google Scholar
• MONTGOMERY JA, NIWAS S, ROSE JD et al.: Structure- based design of inhibitors of purine nucleoside phos-phorylase. 1. 9-(Arylmethyl) derivatives of 9-deazaguanine. J. Med. Chem. (1993) 36:55–69.
   Google Scholar
• ••Detailed account of the structure-based design of PNPinhibitors.
   Google Scholar
• NIWAS S, CHAND P, PATHAK VP, MONTGOMERY JA: Structure-based design of inhibitors of purine nucleoside phosphorylase. 5. 9-deazahypoxanthines. J. Med. Chem. (1994) 37:2477-2480. 9-Deazaguanines and 9-deazahypoxanthines are equipo-tent against calf-spleen PNP.
   Google Scholar
• BURLEY SK, PETSKO GA: Aromatic-aromatic interac-tion: a mechanism of protein structure stabilization. Science (1985) 229:23-28. Description of the herringbone arrangement.
   Google Scholar
• STOECKLER JD, EALICK SE, BUGG CE, PARKS RE, Jr.: De-sign of purine nucleoside phosphorylase inhibitors. Fed. Proc. (1986) 45:2773-2778. Determination of the required Ki for PNP inhibitor to attain 99.9% inhibition.
   Google Scholar
• OSBORNE WRA, BARTON RW: Rat model purine nucleo-side phosphorylase deficiency. Immunology (1986) 59:63–67.
   PubMed Web of Science ®Google Scholar
• SLICHTER SJ, DEEG HJ, OSBORNE RA: Inhibition of the enzyme purine nucleoside phosphorylase (PNP) re-duces refractoriness to transfused platelets in a dog model. Br. J. Haematol (1990) 75:591–597.
   PubMedGoogle Scholar
• BENEAR JB, FREDERICK D, TOWNSEND L, EPSTEIN RB: Prolongation of skin graft survival in dogs treated with 8-aminoguanosine. Transplantation (1986) 41:274-276. Evidence for the immunosuppressive properties of 8-aminoguanosine.
   Google Scholar
• TUTTLE JV, KRENITSKY TA: Effects of acyclovir and its metabolites on purine nucleoside phosphorylase. J. Biol. Chem. (1984) 259:4065–4069.
   PubMed Web of Science ®Google Scholar
• •Acyclovir diphosphate was found to be a very potent PNP inhibitor. The mono- and triphosphates were less active.
   Google Scholar
• KRENITSKY TA, TUTTLE JV, MILLER WH, MOORMAN AR, ORR GF, BEAUCHAMP L: Nucleoside analogue inhibi-tors of purine nucleoside phosphorylase. J. Biol. Chem. (1990) 265:3066–3069.
   PubMed Web of Science ®Google Scholar
• NAKAMURA CE, CHU S-H, STOECKLER JD, PARKS JR RE: Inhibition of purine nucleoside phosphorylase by 9-(phosphonoalkyl)hypoxanthines. Biochem. Pharma-col. (1986) 35:133–136.
   PubMed Web of Science ®Google Scholar
• •Analogues of acyclovir diphosphate are less potent than acyclovir diphosphate itself.
   Google Scholar
• NAKAMURA CE, CHU S-H, STOECKLER JD, PARKS RE, Jr.: Inhibition of purine nucleoside phosphorylase by phosphonoalkylpurines. Nucleosides Nucleotides (1989) 8:1039–1040.
   Google Scholar
• GUIDA WC, ELLIOTT RD, THOMAS HJ et al.: Structure-based design of inhibitors of purine nucleoside phos-phorylase. 4. A study of phosphate mimics. J. Med. Chem. (1994) 37:1109–1114.
   Google Scholar
• HALAZY S, EHRHARD A, DANZIN C: 9-(Difluorophos-phonoalkyOguanines as a new class of multisubstrate analogue inhibitors of purine nucleoside phosphory-lase. J. Am. Chem. Soc. (1991) 113:315–317.
   Web of Science ®Google Scholar
• MAMONT PS, WEIBEL M, DANZIN C, HALAZY S: Effects of9-(difluorophosphonoalkyOguanines, a new class of multisubstrate analogue inhibitors of purine nucleo-side phosphorylase in cultured human leukemic lym-phoblast Molt-4-cells. Intern. J. Purine Pyrim. Res. (1991) 2:62. © Ashley Publications Ltd. All rights reserved.Exp. Opin. Ther. Patents (1998) 8(3)
   Google Scholar
• SEDIVA K, ANANEY AV, VOTRUBAI, HOLY A, ROSEN-BERG I: Inhibition of purine nucleoside phosphory-lase by phosphonomethoxyalkyl analogues of nucleotides. Intern J. Purine Pyrim. Res. (1991) 2:35. Description of acyclic phosphonate inhibitors.
   Google Scholar
• SECRIST III JA, NIWAS S, ROSE JD et al: Structure-based design of inhibitors of purine nucleoside phosphory-lase. 2. 9-Alicylic and 2-heteroalicylcic derivatives of 9-deazaguanine. J. Med. Chem. (1993) 36:1847–1854.
   Google Scholar
• ••Detailed account of the structure-based design of PNPinhibitors.
   Google Scholar
• ERION MD, NIEAS S, ROSE JD et al: Structure-based de- sign of inhibitors of purine nucleoside phosphory-lase. 3. 9-Arylmethyl derivatives of 9-deazaguanine substituted in the methylene group. J. Med. Chem. (1993) 36:3771–3783.
   Google Scholar
• ••Detailed account of the structure-based design of PNPinhibitors.
   Google Scholar
• MONTGOMERY JA, SNYDER JR HVV, WALSH DA, WALSH GM: BCX-34. Purine nucleoside phosphorylase (PNP) inhibitor. Drugs Future (1993) 18:887–890.
   Google Scholar
• ••Preliminary account of the clinical activity of BCX-34 (peld-esine).
   Google Scholar
• HALAZY S, EGGENSPILLER A, EHARD A, DANCIN C: Phos- phonate derivative of N9-benzylguanine: a new class of potent purine nucleoside phosphorylase inhibitor. Bioorg. Med. Chem. Lett. (1992) 2:407–410.
   Web of Science ®Google Scholar
• •Phosphonate derivatives of 9-benzylguanine.
   Google Scholar
• KELLY JL, LINN JA, MCLEAN EW, TUTTLE JV: 9-[(Phos- phonoalkyfibenzyDguanines. Multisubstrate ana-logue inhibitors of human erythrocytic purine nucleoside phosphorylase. J. Med. Chem. (1993) 36:3455–3463.
   Google Scholar
• •Phosphonate derivatives of 9-benzylguanine.
   Google Scholar
• GILBERTSON RB, DONG MK, JOSYULA U, SIRCAR JC, WIL- BURN DJ, CONROY MC: Activities of two 9-deazaguanine analogue inhibitors of purine nucleo-side phosphorylase, CI-972 and PD 141955 in vitro and in vivo. Ann. NY Acad. Sci. (1993) 685:248–251.
   PubMedGoogle Scholar
• •Description of the activity of PD 141955 (CI–1000).
   Google Scholar
• GILBERTSEN RB, JOSYULA U, SIRCAR JC et al.: Compara- tive in vitro and in vivo activities of two 9-deazaguanine analogue inhibitors of purine nucleo-side phosphorylase CI-972 and PD 141955. Biochem. Pharmacol (1992) 44:996–999.
   PubMed Web of Science ®Google Scholar
• •Description of the activity of PD 141955 (CI–1000).
   Google Scholar
• WILBURN DJ, CONG MK, GILBERTSON RB: PD 141955 and CI-972: 9-deaza guanine analogue purine nucleo-side phosphorylase inhibitors. I. Suppression of the human mixed lymphocyte reaction (MLR). Agents Ac-tions (1993) 39.
   Google Scholar
• •Description of the activity of PD 141955 (CI–1000).
   Google Scholar
• DONG MK, GILBERTSEN RB: PD 141955 and CI-972: 9- deazaguanine analogue purine nucleoside phospho-rylase inhibitors. II. Effects on nucleoside catabolism in human and rat blood in vitro. Agents Actions (1993) 39.
   Google Scholar
• •Description of the activity of PD 141955 (CI–1000).
   Google Scholar
• SIRCAR, JC, KOSTLAN CR, GILBERTSON RB, BENNETT MK,DONG MK, CETENKO WJ: Inhibitors of human purine nucleoside phophorylase. Synthesis of pyr-rolo[3,2-4pyrimidines, a new class of purine nucleo-side phosphorylase inhibitors as potentially T-cell se-lective immunosuppressive agents. Description of 2,6-diamino-3,5-dihydro-7-(3-thienylmethyl)-411-pyrrolo[3,2-4pyrimidin-4-one. J. Med. Chem. (1992) 35:1605–1609.
   Google Scholar
• DONG MK, SCOTT ME, SCHRIER DJ et al.: The biochemis-try ad pharmacology of PD 116124 (8-amino-2'-nord-eoxyguanosine), an inhibitor of purine nucleoside phosphorylase (PNP). J. Pharm. Exp. Ther. (1992) 260:319–325.
   PubMedGoogle Scholar
• •Description of the activity of PD 116124.
   Google Scholar
• GILBERTSON RB, SCOTT ME, DONG MK et al: Prelimi- nary report on 8-amino-9-(2-thienylmethyfiguanine (PD 119229), a novel and potent purine nucleoside phosphorylase inhibitor. Agents Action (1987) 21:272–274.
   PubMedGoogle Scholar
• •Description of the activity of PD 119229 (CI–950).
   Google Scholar
• GILBERTSON RB, DONG MK, KOSSAREK LM: Aspects of the purine nucleoside phosphorylase (PNP) deficient state product in normal rats following oral administra-tion of 8-amino-9-(2-thienylmethyDguanine (PD 119229), a novel inhibitor of PNP. Agents Action (1987) 22:379–384.
   Google Scholar
• •Description of the activity of PD 119229 (CI–950).
   Google Scholar
• SIRCAR JC, KOSTLAN CR, PINTER GW et al.: 8-Amino-9- substituted guanines: potent purine nucleoside phos-phorylase (PNP) inhibitors. Agents Action (1987) 21:253–256.
   PubMedGoogle Scholar
• •Description of the activity of PD 119229 (CI–950).
   Google Scholar
• GILBERTSON RB, DONG MK, KOSSAREK LM, SIRCAR JC,KOSTLAN CR, CONROY MC: Selective in vitro inhibition of human MOLT-4 T lymphoblasts by the novel purine nucleoside phosphorylase inhibitor, CI-972. Biochem. Biophys. Res. Comm. (1991) 178:1351–1358.
   PubMedGoogle Scholar
• ELLIOTT AJ, KOTIAN PL, MONTGOMERY JA, WALSH DA:Synthesis of pyrrolo[3,2-d]pyrimidines (9-deazaguanines) by reductive cyclodeamination reac-tions. Tetrahedron Lett. (1996) 37:5829-5830. BioCryst's preparation of 9- (3-thienylmethyl)- 9-deazaguanine.
   Google Scholar
• BENNETT LL, ALLAN PW, NOKER PE eta].: Purine nucleo-side phosphorylase inhibitors: biochemical and phar-macological studies with 9-benzy1-9-deazaguanine and related compounds. J. Exp. Pharmacol. Ther. (1993) 266:707–714.
   Google Scholar
• •9-Benzy1-9-deazaguanine raises inosine levels and increases the half-life of ddI in rats.
   Google Scholar
• BANTIA S, MONTGOMERY JA, JOHNSON HG, WALSH GM: In vivo and in vitro pharmacologic activity of the pu-rine nucleoside phosphorylase inhibitor BCX-34: the role of GTP and dGTP. Immunopharmacology (1996) 35:53–63.
   PubMedGoogle Scholar
• ••dGTP does not accumulate in rodents and T-cell prolifera-tion is not inhibited when rats are treated with BCX-34 (peldesine). © Ashley Publications Ltd. All rights reserved.Exp. Opin. Ther. Patents (1998) 8(3)
   Google Scholar